What does Annovis Bio, Inc. do?
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405,…
What is Annovis Bio, Inc.'s P/E and P/B ratio?
Annovis Bio, Inc. has a P/E ratio of -0.6 and a P/B ratio of -9.95.
What is Annovis Bio, Inc.'s debt-to-equity ratio?
Annovis Bio, Inc. has a debt-to-equity ratio of 0.00.
How much does Annovis Bio, Inc. owe compared with what it owns?
Annovis Bio, Inc. owes $1.19 for every $1 it owns (balance sheet Jun 2026), which means it owes more than it owns.
What is Annovis Bio, Inc.'s Positivity rank?
Annovis Bio, Inc. is ranked #6,497 of 6,775 companies globally and #3,746 of 4,000 in United States on PositoAI, with a Positivity Score of -21,405.
Does Annovis Bio, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Annovis Bio, Inc..
Where can I read the latest news about Annovis Bio, Inc.?
Recent headlines about Annovis Bio, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Annovis Bio, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Annovis Bio, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.